STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,000 | -43.8% | 4,632 | +56.5% | 0.00% | – |
| Q2 2023 | $32,000 | +190.9% | 2,959 | +120.5% | 0.00% | – |
| Q1 2023 | $11,000 | -76.1% | 1,342 | -73.3% | 0.00% | – |
| Q4 2022 | $46,000 | +820.0% | 5,021 | +1318.4% | 0.00% | – |
| Q3 2022 | $5,000 | +66.7% | 354 | +71.0% | 0.00% | – |
| Q2 2022 | $3,000 | -88.9% | 207 | -83.5% | 0.00% | – |
| Q1 2022 | $27,000 | -72.2% | 1,253 | -69.0% | 0.00% | – |
| Q4 2021 | $97,000 | +136.6% | 4,048 | +153.3% | 0.00% | – |
| Q3 2021 | $41,000 | -6.8% | 1,598 | +22.3% | 0.00% | – |
| Q2 2021 | $44,000 | -13.7% | 1,307 | +0.2% | 0.00% | – |
| Q1 2021 | $51,000 | +920.0% | 1,304 | +1593.5% | 0.00% | – |
| Q4 2020 | $5,000 | +400.0% | 77 | +87.8% | 0.00% | – |
| Q2 2020 | $1,000 | -50.0% | 41 | -53.9% | 0.00% | – |
| Q1 2020 | $2,000 | -91.7% | 89 | -89.5% | 0.00% | – |
| Q4 2019 | $24,000 | – | 848 | +3754.5% | 0.00% | – |
| Q3 2019 | $0 | – | 22 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $666,561,000 | 74.20% |
| RTW INVESTMENTS, LP | 3,644,248 | $141,543,000 | 2.21% |
| Redmile Group, LLC | 2,544,062 | $98,811,000 | 1.39% |
| Cormorant Asset Management, LP | 1,437,807 | $55,844,000 | 1.24% |
| ACUTA CAPITAL PARTNERS, LLC | 45,000 | $1,748,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 150,729 | $5,854,000 | 0.45% |
| HighVista Strategies LLC | 13,692 | $532,000 | 0.40% |
| Birchview Capital, LP | 15,000 | $583,000 | 0.35% |
| Perceptive Advisors | 671,978 | $26,100,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,265,950 | $49,169,000 | 0.26% |